Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial;Prophylaxie post-exposition ou traitement préventif pour le syndrome respiratoire aigu sévère du coronavirus 2 (SARS-CoV-2) : protocole d’étude pour une étude randomisée contrôlée pragmatique

Canadian Journal of Anesthesia

Volumn 67, Issue 9, 2020, Pages 1201-1211

  Lother, Sylvain A ^a   Abassi, Mahsa ^b   Agostinis, Alyssa ^c,d   Bangdiwala, Ananta S ^e   Cheng, Matthew P ^f,g   Drobot, Glen ^a   Engen, Nicole ^e   Hullsiek, Kathy H ^e   Kelly, Lauren E ^a   Lee, Todd C ^h   Lofgren, Sarah M ^b   MacKenzie, Lauren J ^a   Marten, Nicole ⁱ   McDonald, Emily G ^h   Okafor, Elizabeth C ^b   Pastick, Katelyn A ^b   Pullen, Matthew F ^b   Rajasingham, Radha ^b   Schwartz, Ilan ^c   Skipper, Caleb P ^b   Turgeon, Alexis F ^j,k   Zarychanski, Ryan ^a,l   Boulware, David R ^b   more..

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSITY OF MINNESOTA   (United States)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ ST BONIFACE GENERAL HOSPITAL   (Canada)

^j LAVAL UNIVERSITY   (Canada)

^k UNIVERSITÉ LAVAL   (Canada)

^l CANCERCARE MANITOBA   (Canada)

more..

Author keywords

clinical trials; coronavirus; COVID 19; healthcare worker; Hydroxychloroquine; post exposure prophylaxis; pre emptive therapy; SARS CoV 2

Indexed keywords

HYDROXYCHLOROQUINE SULFATE; PLACEBO; HYDROXYCHLOROQUINE;

ADULT; ARTICLE; CANADA; CLINICAL TRIAL PROTOCOL; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DEATH; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPOSURE; FOLLOW UP; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HOSPITALIZATION; HOUSEHOLD; HUMAN; INFORMED CONSENT; INTENSIVE CARE; INTERNATIONAL COOPERATION; INTERNET; LOADING DRUG DOSE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PANDEMIC; PATIENT SELECTION; POST EXPOSURE PROPHYLAXIS; PRAGMATIC TRIAL; PRE EMPTIVE THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS; RISK REDUCTION; SOCIAL DISTANCING; STUDY DESIGN; TREATMENT DURATION; UNITED STATES; VIRUS TRANSMISSION; BETACORONAVIRUS; CLINICAL TRIAL; CORONAVIRUS INFECTION; ISOLATION AND PURIFICATION; PROCEDURES; SEVERITY OF ILLNESS INDEX; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DOUBLE-BLIND METHOD; HUMANS; HYDROXYCHLOROQUINE; PANDEMICS; PNEUMONIA, VIRAL; POST-EXPOSURE PROPHYLAXIS; SEVERITY OF ILLNESS INDEX;

EID: 85084617217     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-020-01684-7     Document Type: Article

References (41)

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5: 536-44.
2. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19); 2020. Available from URL: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (accessed April 2020).
3. Public Health Agency of Canada. Coronavirus disease (COVID-19): Prevention and risks; 2020. Available from URL: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html (accessed April 2020).
4. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) - Infection Control; 2020. Available from URL: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html (accessed April 2020).
5. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 2020; DOI: 10.3785/j.issn.1008-9292.2020.03.03. DOI: 10.3785/j.issn.1008-9292.2020.03.03
6. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72-3. DOI: 10.5582/bst.2020.01047
7. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; DOI: 10.1016/j.ijantimicag.2020.105949. DOI: 10.1016/j.ijantimicag.2020.105949
8. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020; DOI: https://doi.org/10.1101/2020.03.22.20040758 (accessed April 2020).
9. Alhazzani W, Moller MH, Arabi YM, et al. Surviving sepsis campaign - guidelines on the management of critically ill adults with coronavirus disease 2019 COVID-19. Crit Care Med 2020; DOI: 10.1097/CCM.0000000000004363. DOI: 10.1097/CCM.0000000000004363
10. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19; 2020. Available from URL: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (accessed April 2020).
11. Linton NM, Kobayashi T, Yang Y, et al. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. J Clin Med 2020; DOI: 10.3390/jcm9020538. DOI: 10.3390/jcm9020538
12. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; DOI: 10.1056/NEJMoa2002032. DOI: 10.1056/NEJMoa2002032
13. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; DOI: 10.1001/jama.2020.2648. DOI: 10.1001/jama.2020.2648
14. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199-207. DOI: 10.1056/NEJMoa2001316
15. Bialek S, Boundy E, Bowen V, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 343-6. DOI: 10.15585/mmwr.mm6912e2
16. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging. novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020; DOI: 10.1002/jmv.25748. DOI: 10.1002/jmv.25748
17. Sanche S, Lin YT, Xu C, et al. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 2020; DOI: 10.3201/eid2607.200282. DOI: 10.3201/eid2607.200282
18. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 245-6. DOI: 10.15585/mmwr.mm6909e1
19. Liu Y, Eggo RM, Kucharski AJ. Secondary attack rate and superspreading events for SARS-CoV-2. Lancet 2020; DOI: 10.1016/S0140-6736(20)30462-1. DOI: 10.1016/S0140-6736(20)30462-1
20. Pastick KA, Okafor EC, Wang F, et al. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis 2020; DOI: 10.1093/ofid/ofaa130. DOI: 10.1093/ofid/ofaa130
21. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; DOI: 10.1186/1743-422X-2-69. DOI: 10.1186/1743-422X-2-69
22. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; DOI: 10.1093/cid/ciaa237. DOI: 10.1093/cid/ciaa237
23. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020; DOI: 10.1093/jac/dkaa114. DOI: 10.1093/jac/dkaa114
24. Borba MG, de Almeida Val F, Sampaio VS, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection:pPreliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv 2020; DOI: https://doi.org/10.1101/2020.04.07.20056424.
25. Lexi Drugs. Chloroquine. Hudson, OH: Lexi-Comp Inc.; 2020. Available from URL: https://online.lexi.com/lco/action/login (accessed April 2020).
26. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 1983; 75: 11-8. DOI: 10.1016/0002-9343(83)91265-2
27. Lexi Drugs. Hydroxychloroquine. Hudson, OH: Lexi-Comp Inc.; 2016. Available from URL: https://online.lexi.com/lco/action/login (accessed April 2020).
28. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv 2020; DOI: https://doi.org/10.1101/2020.04.10.20060558.
29. Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; DOI: 10.1016/j.medmal.2020.03.006. DOI: 10.1016/j.medmal.2020.03.006
30. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; DOI: 10.1001/jama.2020.1585. DOI: 10.1001/jama.2020.1585
31. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet 2020; 395: 497-506. DOI: 10.1016/S0140-6736(20)30183-5
32. Mahevas M, Tran VT, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv 2020: DOI: https://doi.org/10.1101/2020.04.10.20060699.
33. International Society of Nephrology. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease; 2012. Kidney International Supplements January 2013. Available from URL: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf (accessed April 2020).
34. Organization of Teratology Information Specialists (OTIS). Mother to Baby Fact Sheet. Hydroxychloroquine. Available from URL: https://mothertobaby.org/fact-sheets/hydroxychloroquine-pregnancy/pdf/. Published 2018. Accessed April 5, 2020 (accessed April 2020).
35. Centers for Disease Control and Prevention. Treatment of Malaria (Guidelines for Clinicians); 2019. Available from URL: https://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf. (accessed April 2020).
36. World Health Organization. Global surveillance for human infection with coronavirus disease (COVID-19); 2020. Available from URL: https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov) (accessed April 2020).
37. World Health Organization. COVID-19 Therapeutic Trial Synopsis; 2020. Available from URL: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf (accessed April 2020).
38. Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic testing for severe acute respiratory syndrome-related coronavirus-2: a narrative review. Ann Intern Med 2020; DOI: 10.7326/M20-1301. DOI: 10.7326/M20-1301
39. Centers for Disease Control and Prevention. Information for clinicians on investigational therapeutics for patients with COVID-19; 2020. Available from URL: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html (accessed April 2020).
40. Cheng MP, Lee TC, Tan DH, Murthy S. Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. CMAJ 2020; DOI: 10.1503/cmaj.200438. DOI: 10.1503/cmaj.200438
41. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonial. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia (Chinese). Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: 185-8.